January 25, 2021 -- Precision BioSciences has received a notice of allowance from the U.S. Patent and Trademark Office for patent application, No. 16/908, 030. The patent application covers PBCAR19B, a next-generation, stealth cell, CD19 allogeneic chimeric antigen receptor (CAR) T candidate for patients with relapsed/refractory non-Hodgkin lymphoma.
The application included genetically modified human T cells comprising the company's PBCAR19B construct, which is inserted within the T-cell receptor alpha constant (TRAC) locus. The construct is designed to improve the allogeneic persistence of CAR T cells following infusion by reducing rejection by T cells and natural killer cells. The technology was developed on the company's Arcus genome editing platform.
The new patent will expire in April 2040.
The U.S. Food and Drug Administration accepted the investigational new drug application for PBCAR19B, and the phase I clinical study is expected to begin by mid-2021. Servier has the exclusive right to opt in for late-stage development and commercialization, and Precision has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the U.S.